Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2110183 in Proteasome Inhibitor Refractory Multiple Myeloma
NCT01445587Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afuresertib in multiple myeloma (MM), sponsored by GSK. Planned start Nov 2011; status: withdrawn.
02
Drugs
afuresertib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01445587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01445587.